General MedicationsINTRAMUSCULARStandard

ZYPREXA RELPREVV

OLANZAPINE PAMOATE

Standard Dose

EQ 300MG BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview ZYPREXA RELPREVV is listed in Drugs@FDA under application 022173 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OLANZAPINE PAMOATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - EQ 300MG BASE/VIAL Sponsor CHEPLAPHARM Submission history Latest submission status date: 2026-01-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZYPREXA RELPREVV is listed in Drugs@FDA under application 022173 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient OLANZAPINE PAMOATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - EQ 300MG BASE/VIAL Sponsor CHEPLAPHARM Submission history Latest submission status date: 2026-01-30 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.